Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134758) titled 'Predictors of Belimumab Efficacy in Refractory Lupus Nephritis' on Oct. 20.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Shanghai General Hospital

Condition: Refractory Lupus Nephritis

Intervention: 6-Month Complete Renal Remission Group

Recruitment Status: Recruiting

Phase: 4

Date of First Enrollment: 2026-01-19

Target Sample Size: 6-Month Complete Renal Remission Group; 6-Month Non-Complete Renal Remission Group:28;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=337250

Disclaimer: Curated by HT Syndication....